Sermorelin vs CJC-1295 + Ipamorelin
The two most-prescribed GH-secretagogue protocols — older single-peptide GHRH analog vs newer dual-mechanism stack.
TL;DR
Sermorelin is a single-peptide GHRH analog with a short half-life (~10 min) that requires nightly dosing. CJC-1295 + Ipamorelin is a dual stack — CJC-1295 is a longer-acting GHRH analog (DAC variant: ~7-day half-life; no-DAC: ~30 min) paired with Ipamorelin, a selective ghrelin-receptor agonist that adds a second, independent GH-release trigger. The stack hits both GH-release pathways at once and is the more common choice in practitioner protocols, but it has never been tested in people. Sermorelin is cheaper and has human trial data; it was FDA-approved as Geref until the product was withdrawn from the US market in 2008.
Side-by-side
How they work — side-by-side
Sermorelin is a 29-amino-acid fragment of natural GHRH (growth-hormone-releasing hormone). It binds the GHRH receptor on pituitary somatotrophs and stimulates a physiologic pulse of growth hormone release. Because it's a GHRH analog working through the body's normal feedback loop, it preserves the pituitary's natural pulsatile rhythm — the trade-off is a short half-life (~10 minutes) that requires nightly dosing, and a relatively mild pulse compared to dual-mechanism stacks.
CJC-1295 + Ipamorelin is a dual-pathway stack. CJC-1295 (typically the 'no-DAC' variant) is a longer-acting GHRH analog — same target as sermorelin but engineered for a slightly longer half-life. Ipamorelin is a selective ghrelin receptor agonist (a 'GHRP' — growth-hormone-releasing peptide) that triggers GH release through an entirely different receptor than GHRH. Hitting both receptors at the same time produces a synergistic GH pulse that's stronger than either component alone.
The Ipamorelin selectivity is part of why the stack got popular: older GHRPs (GHRP-2, GHRP-6) trigger meaningful cortisol and prolactin release alongside GH, which is unwanted in most protocols. Ipamorelin was engineered to be selective for the GH-release pathway with minimal cortisol/prolactin spillover. Practitioners report stronger IGF-1 responses with the stack than with sermorelin alone; the two have not been compared in a trial.
When to choose which
Sermorelin
Choose Sermorelin if
Sermorelin is the better choice when cost, human trial data, or a gentler physiologic profile matters more than peak GH-pulse magnitude.
- Cost-sensitive — sermorelin runs $100–200/mo vs $150–300/mo for the stack
- You want a peptide with human trial data (sermorelin) rather than one never tested in people (CJC no-DAC + Ipa)
- You want a gentler, more physiologic GH-pulse profile
- First-time GH-secretagogue user wanting the simpler single-peptide protocol
CJC-1295 + Ipamorelin
Choose CJC-1295 + Ipamorelin if
The dual stack is the better choice when stronger IGF-1 response, dual-pathway mechanism, or body-recomposition goals are the priority.
- Stronger GH pulse and IGF-1 elevation is the goal
- Body recomposition or fat-loss outcomes are a primary endpoint
- Sermorelin produced too mild a response in prior protocols
- You want the dual-mechanism (GHRH + ghrelin) approach
- You're prepared for shorter cycles (8–12 weeks) with breaks vs continuous sermorelin
Sequence not stack
Don't stack sermorelin with CJC-1295 — both target the same GHRH receptor, and adding sermorelin to a CJC-1295 protocol is redundant. The valid layering is GHRH + GHRP, which is exactly what CJC-1295 + Ipamorelin already provides. If you want to layer sermorelin with a second mechanism, pair it with Ipamorelin (sermorelin + ipamorelin is a recognized stack), not with another GHRH analog.
Safety + side-effect contrast
Both protocols have favorable real-world safety profiles compared to exogenous HGH because they work through the body's own pulsatile GH-release system rather than overriding it. Differences are at the margins.
- Both can produce mild water retention, transient morning grogginess, or temporary numbness/tingling in extremities at higher doses.
- The CJC+Ipamorelin stack carries slightly higher cortisol and prolactin risk than sermorelin alone, though Ipamorelin's selectivity minimizes this vs older GHRPs.
- Sermorelin has human trial data (children with GH deficiency, older adults); the CJC-1295 no-DAC + Ipamorelin stack has none.
- Neither is appropriate during active malignancy — both increase IGF-1 and can theoretically accelerate tumor growth.
- Both require a break from continuous use — typically 8–12 week cycles for the stack, 3–6 month courses with breaks for sermorelin.
Frequently asked
Is CJC-1295 + Ipamorelin better than Sermorelin?
The stack hits two independent GH-release receptors, so practitioners expect a stronger GH pulse and IGF-1 rise than with sermorelin alone, but the two have never been compared in a trial and the stack has never been tested in people. Sermorelin has human trial data and costs less. The right answer depends on your goal and risk tolerance.
Can I take Sermorelin with CJC-1295?
Avoid this combination — both are GHRH analogs targeting the same receptor, so stacking them is redundant. If you want a dual-pathway approach, pair a GHRH analog (sermorelin OR CJC-1295) with a GHRP (Ipamorelin). The canonical pairings are Sermorelin + Ipamorelin or CJC-1295 + Ipamorelin.
How long until I see results?
Sermorelin typically shows IGF-1 changes by 4–6 weeks and subjective improvements (sleep depth, recovery, body composition) by 8–12 weeks. The CJC-1295 + Ipamorelin stack tends to produce noticeable changes faster — 2–4 weeks for sleep and recovery, 6–8 weeks for body composition.
Do I need to cycle these peptides?
Yes, but the cycling pattern differs. CJC-1295 + Ipamorelin is typically run 8–12 weeks on, then 4–8 weeks off, to prevent receptor desensitization. Sermorelin is more often run continuously for 3–6 months, then a break — its milder pulse profile is gentler on receptor sensitivity.
Is CJC-1295 'no-DAC' the same as Modified GRF 1-29?
Yes — CJC-1295 no-DAC and Modified GRF 1-29 (Mod GRF 1-29) are the same molecule. The 'DAC' (Drug Affinity Complex) version has a different name and a much longer half-life (~7 days) by binding to serum albumin. Most practitioner protocols use the no-DAC variant because it produces cleaner GH pulses without the prolonged-elevation effect.
Cited research
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging, 2006.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006.
Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev, 2018.
Need a personalized sermorelin vs cjc-1295 + ipamorelin call?
The Coach takes your bloodwork, goals, and tolerance into account and outputs a cited protocol card — saved as a branded PDF you can take to your doctor.
Ask the Coach